Business
Presenting at Upcoming Scientific Conferences
Presenting at Upcoming Scientific Conferences.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 4803R Scancell Holdings Plc 12 September 2014 \n \n\n12 September 2014\n \n \nScancell Holdings Plc\n \nScancell to Present at Upcoming Scientific Conferences\n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that Professor Lindy Durrant, Joint CEO of Scancell, is scheduled to present on SCIB1, the Company's clinical stage ImmunoBody® vaccine for the treatment of melanoma, and the ImmunoBody® technology platform at the following conferences: \n \n\n\n\n\nConference \n\n\nPresentation\n\n\nTiming \n\n\n\n\n3rd Annual Cancer Vaccines Conference, London, UK (15-16 September 2014)\n\n\nPhase I/II trial of a novel antibody DNA immunotherapy, SCIB1 ImmunoBody® which targets CD64, in the treatment of melanoma \n\n\n\n15 September 2014 at 15.20 \n\n\n\n\nCancer Antibodies Vaccines/Adjuvants & Delivery Conference (CAVAD 14), Lausanne, Switzerland (17-19 September 2014)\n\n\nPhase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of melanoma\n\n\n\n\n17 September 2014 at 11.30\n\n\n\n\n14th International Conference on Progress in Vaccination Against Cancer (PIVAC-14), Rome, Italy (24-26 September 2014)\n\n\nPhase 1/2 clinical trial of SCIB1 ImmunoBody® in stage III/IV melanoma\n\n\n\nTBC\n\n\n\n\n \n \nProfessor Lindy Durrant will also be on the Scientific Advisory Panel and conference co-chair at CAVAD 14. \n \n \nFor Further Information: \n \n\n\n\n\nScancell Holdings Plc \nDr Richard Goodfellow, Joint CEO \nProfessor Lindy Durrant, Joint CEO \n\n\n\n\n\n+ 44 (0) 74 2323 0 497 \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nFTI Consulting\n\n\n\n\n\n \n+44 (0) 20 3727 1000\n\n\n\n\nSimon Conway\nMo Noonan\n\n\n\n\n\n\n\n\n\n\n \n \nAbout Scancell \n \nScancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effect...